New Inhibitors in the Ageing Population: A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia

Abstract

Introduction A second peak of inhibitors has been reported in patients with severe hemophilia A (HA) aged >50 years in the United Kingdom. The reason for this suggested breakdown of tolerance in the aging population is unclear, as is the potential impact of regular exposure to the deficient factor by prophylaxis at higher age. No data on hemophilia B (HB) have ever been reported.

Aim The ADVANCE Working Group investigated the incidence of late-onset inhibitors and the use of prophylaxis in patients with HA and HB aged ≥40 years.

Methods A retrospective, observational, cohort, survey-based study of all patients aged ≥40 years with HA or HB treated at an ADVANCE hemophilia treatment center.

Results Information on 3,095 people aged ≥40 years with HA or HB was collected. Of the 2,562 patients with severe HA, the majority (73% across all age groups) received prophylaxis. In patients with severe HA, the inhibitor incidence per 1,000 treatment years was 2.37 (age 40–49), 1.25 (age 50–59), and 1.45 (age 60 + ). Overall, the inhibitor incidence was greatest in those with moderate HA (5.77 [age 40–49], 6.59 [age 50–59], and 4.69 [age 60 + ]) and the majority of inhibitor cases were preceded by a potential immune system challenge. No inhibitors in patients with HB were reported.

Conclusion Our data do not identify a second peak of inhibitor development in older patients with hemophilia. Prophylaxis may be beneficial in older patients with severe, and possibly moderate HA, to retain a tolerant state at a higher age.

Keywords

hemophilia A/B - inhibitors - prophylaxis - aging

Publikationsverlauf

Eingereicht: 27. April 2021

Angenommen: 09. September 2021

Accepted Manuscript online:
10. September 2021

Artikel online veröffentlicht:
05. November 2021

• References

• 1 Abdi A, Linari S, Pieri L, Voorberg J, Fijnvandraat K, Castaman G. Inhibitors in nonsevere haemophilia A: what is known and searching for the unknown. Semin Thromb Hemost 2018; 44 (06) 568-577
• 2 Schep SJ, Boes M, Schutgens REG, van Vulpen LFD. An update on the 'danger theory' in inhibitor development in hemophilia A. Expert Rev Hematol 2019; 12 (05) 335-344
• 3 Hassan S, Cannavò A, Gouw SC, Rosendaal FR, van der Bom JG. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review. J Thromb Haemost 2018; 16 (06) 1055-1068
• 4 Kempton CL. Inhibitors in previously treated patients: a review of the literature. Haemophilia 2010; 16 (102) 61-65
• 5 Lillicrap D, Fijnvandraat K, Santagostino E. Inhibitors - genetic and environmental factors. Haemophilia 2014; 20 (Suppl. 04) 87-93
• 6 Santagostino E, Auerswald G, Benson G. et al. Switching treatments in haemophilia: is there a risk of inhibitor development?. Eur J Haematol 2015; 94 (04) 284-289
• 7 Ljung R, Auerswald G, Benson G. et al. Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. Eur J Haematol 2019; 102 (02) 111-122
• 8 Hay CR, Palmer B, Chalmers E. et al; United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO). Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117 (23) 6367-6370
• 9 Eckhardt CL, van der Bom JG, van der Naald M, Peters M, Kamphuisen PW, Fijnvandraat K. Surgery and inhibitor development in hemophilia A: a systematic review. J Thromb Haemost 2011; 9 (10) 1948-1958
• 10 Kim JY, You CW. The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A. Blood Res 2019; 54 (03) 204-209
• 11 Hemlibra. Summary of product characteristics. Accessed February 27, 2021 at: https://www.ema.europa.eu/en/medicines/human/EPAR/hemlibra#product-information-section
• 12 Aledort L, Mannucci PM, Schramm W, Tarantino M. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus 2019; 17 (06) 479-486
• 13 Fischer K, Lassila R, Peyvandi F. et al; EUHASS participants. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost 2015; 113 (05) 968-975
• 14 Bachelet D, Albert T, Mbogning C. et al; ABIRISK consortium. Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A. PLoS One 2019; 14 (06) e0218258
• 15 Peyvandi F, Garagiola I. Product type and other environmental risk factors for inhibitor development in severe hemophilia A. Res Pract Thromb Haemost 2018; 2 (02) 220-227
• 16 Gouw SC, van den Berg HM, Fischer K. et al; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013; 121 (20) 4046-4055
• 17 Santoro C, Quintavalle G, Castaman G. et al. Inhibitors in hemophilia B. Semin Thromb Hemost 2018; 44 (06) 578-589
• 18 DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138 (03) 305-315
• 19 Giuffrida AC, Genesini S, Franchini M, De Gironcoli M, Aprili G, Gandini G. Inhibitors in mild/moderate haemophilia A: two case reports and a literature review. Blood Transfus 2008; 6 (03) 163-168
• 20 Hay CRM, Ludlam CA, Colvin BT. et al; UK Haemophilia Centre Directors Organisation. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Thromb Haemost 1998; 79 (04) 762-766
• 21 Sharathkumar A, Lillicrap D, Blanchette VS. et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1 (06) 1228-1236
• 22 Abdi A, Kloosterman FR, Eckhardt CL. et al; INSIGHT Study Group. The factor VIII treatment history of non-severe hemophilia A. J Thromb Haemost 2020; 18 (12) 3203-3210